Table 2: Plasma levels of SDF1α and other parameters in 39 patients with type 2 diabetes.
Values are expressed as mean±SD, ACR values are expressed in median and extremes, #: stastistical difference vs. Pre-treatment , *: stastical difference vs. Non-inhibitor group , SDF1: stromal cell-derived factor 1 alpha, HOMA-IR: Homeostasis model assessment of insulin resistance, NGSP: Revised by the Glycohemoglobin Standarization Program, eGFR: estimated glomerular filtration rate
Pre-treatment | | Non-inhibitor group | | DPP4 inhibitor group | |
| | n=19 | | n=20 | |
SDF1α | [Mmol/L] | 210.3±69.3 | | 204.5±70.4 | |
Thrombomodulin | [FU/mL] | 3.11±1.04 | | 3.15±1.26 | |
HOMA-IR | | 2.63±2.29 | | 2.54±2.98 | |
Hemoglobin A1c(NGSP) | | 7.28±1.44 | | 7.26±1.22 | |
8-hydroxydexyguanosine | [%] | 36.7±13.1 | | 40.0±13.9 | |
eGFR | [Ng/mmolCr] | 74.0±25.9 | | 68.9±19.9 | |
Albumin creatinnine ratio | [mL/min] | 4.68±3.85 | | 5.51±5.18 | |
Median(interquartile range) | [Mg/mmolCr] | 2.36(0.97-7.00) | | 3.81(1.75-6.78) | |
Post-treatment | | | (P value#) | | (P value#) |
SDF1α | [mmol/L] | 207.0±63.4 | (0.9302) | 355.1±80.1# | (0.0001#) |
Thrombomodulin | [FU/mL] | 2.99±1.22 | (0.7478) | 2.88±1.13 | (0.4993) |
HOMA-IR | | 2.56±1.65 | (0.7258) | 2.12±2.67 | (0.3049) |
Hemoglobin A1c(NGSP) | [%] | 7.26±1.25 | (0.9766) | 6.23±1.42 | (0.2050) |
8-hydroxydexyguanosine | [ng/mmolCr] | 35.9±11.8 | (0.8380) | 27.6±10.4 | (0.5552) |
eGFR | [ml/min] | 73.6±24.4 | (0.8955) | 64.7±21.3 | (0.3914) |
Albumin creatinnine ratio | [mg/mmolCr] | 4.99±7.76 | | 3.25±4.46 | |
Median(interquartile range) | | 2.41(0.44-5.95) | (0.7042) | 2.13#(0.85-3.01) | (0.042#) |
%alteration | | | | | (P value*) |
SDF1α | 98±23 | | 174±38* | | (<0.0001*) |
Thrombomodulin | 96±11 | | 91±13* | | (0.0143) |
HOMA-IR | 97±94 | | 83±85 | | (0.0841) |
Hemoglobin A1c(NGSP) | 100±7 | | 86±8* | | (0.0003*) |
8-hydroxydexyguanosine | 99±19 | | 69±26* | | (0.0009*) |
eGFR | 99±11 | | 94±10* | | (0.0005*) |
| 107±82 | | 59±39* | | (0.0007*) |